Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Vaccines (Basel)
Egile Nagusiak: Azzari, Chiara, Moriondo, Maria, Nieddu, Francesco, Guarnieri, Valentina, Lodi, Lorenzo, Canessa, Clementina, Indolfi, Giuseppe, Giovannini, Mattia, Napoletano, Giuseppina, Russo, Francesca, Baldovin, Tatjana, Cocchio, Silvia, Ricci, Silvia, Baldo, Vincenzo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563708/
https://ncbi.nlm.nih.gov/pubmed/32842669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030469
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak